@GoldenMindTrade
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is a solid investment, so solid I don't check everyday and obsess, I know what I own. Cheers all, big things coming.
Thanks for sharing, im really looking forward to the 10k, and just thinking where this will be in a few years is crazy.
I overslept?? hahaha celebrating a big bonus, guess where some if that's headed into
Smart man. 5 mil volume has been my alert on $USRM for the last few months. The only time I really look at it now. I know what I own and don't plan to sell for a while. Cheers to the future of medicine. Everyone I show this company too goes crazy :)
It's common sense. No need to watch this joard or even check in every day. We know what we own and I always buy more when I can. This is the future....some people won't like it and others will. This is the easiest investment I've seen in a while if you ask me
Cheers to everyone.
Hahaha that's fine I'd love more 14s but sad I don't think it'll get that low. Looking for a strong close to the week
Glad to be part of such a special company and see the support across social media, especially the FB page. This is hugeeeeeeeee
That was sooooooo perfect... pay attention to the everything thats going on ;) THIS is Huuuuuuuuuge. $USRM is a dollar stock. PERIOD.
CHEERS!
Cheers to all investors :)
This is the future of medicine. The facts are in the science and the growing demand. The world is coming around and I for sure want to have easy access for this for my family and myself.
Imagine this tech could do to you and your family in the future. Support it. Trust the process. I love this company and what they stand for.
I always love reading that article, thanks again
$1 on the way looks like, and it's funny cause I've never felt so confident saying that. Market cap here is a joke a straight joke compared to what it should be good luck all, cheers
Follow the bread crumbs :)
Just impatient investors, know what your buying, I sure do :). If you look at the story of what USRM has been through it's miraculous and the growth is unheard of for a market cap this low. sector heating up, $USRM looking great
This should be a dollar stock if you ask me and it seems many agree. Looking forward to game changing news, this Jack in the box is about to pop
Especially since most of them can benefit from the recent news.
Huge exposure here coming :)
Saving people's lives one treatment at a time, cheers
Everyone's very excited about all the new clinics especially the Kuwait one mentioned in last few quarterly reports.
Cant wait :)
Wayyy undervalued and people are realizing this cheers all
This is bigger then anyone can imagine. Cheers to all who have been accumulating.
I feel like I know CGRW better then myself hahahhaa congrats all once again :)
Wrong again. USRM continues to prosper and grow. Thanks all!!!!
Merry Christmas all, excited to continue this massive growth into 2018, Kuwait on the way :). Cheers :)
Definitely an anomaly, interested to see this see the valuation is deswrves. Exepecting some news before year end
You see John, this is the activity I was looking for hahaha, cheers. In at $.6 for the long haul.
Yeah my presictions keep raising the more I see. Crazy to thibk what this will be once off the greys and what exchange..were on track for a few dollars a share easy
All thwir issued coins here http://bitcoincapitalcorp.com/our-issued-coins/
Just think it should get some more exposure
Seeing people start to talk about the news today. Wahoo see everyone out the roof when we're off the greys
Thats crazy theres no activity here. When does everyone think greys will end?
CLASSIC TAKE DOWN BEFORE IT RUNs. :). I would say one of the biggest indicators in these OTC stocks is that there tends to be a take down before a big run, you can see it in the stock in early Feb from .0045 to .0025 before going to .02-.03 before .18, look at Cannagrow or MGT I for examples as well before their historic big runs and recent.
Come on end of year sellers where you at? I need to spend some of this litecoin from last year
Wrong again. USRM TOO THE MOOON
In case people forgot $USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 Assets,~X3.5 Cash from Sept 2016-2017, and look to be set up for a move to new highs. USRM brought in $1.5 million in revs & $1 million of gross profit last Q alone
http://www.nasdaq.com/symbol/usrm/revenue-eps
That link above paints a clear picture of where the company is headed
There is so much more going for the company now versus earlier this year when it was trading with a VWAP between $.075-$.14 for 80+ trading days and especially last year or what ever happened almost ten years ago. I am looking forward to more and more revenue growth with overseas expansion with their Kuwait clinic and hopefully more trials and updates on RMAT. One big spark and the game changes.
A $16 million market cap @ $.045 could easily be $100mil market cap which would be ~$.30/share. A valuation correction is well over due if you ask me and it seems others are beginning to agree.
They doubled revs and tripled profits in 1 year and the stem cell market is growing at an insane rate.
https://www.ihealthcareanalyst.com/global-stem-cell-therapy-market/ Mentioned here as Bioheart
"The global stem cells market was approximately 13 billion dollars in 2016, and from 2017, the expected annual growth rate is 14.7%, which would expand the market to 29.6 billion dollars by 2021."
"Major players operating in the global stem cell therapy market and profiled in this report include Aastrom Biosciences, Alliancells Bioscience Co. Ltd., AlloCure, Inc., Anterogen Co. Ltd., Astellas Pharma (Ocata Therapeutics/Advanced Cell Technology), Baxter Healthcare, Bioheart, BrainStorm Therapeutics, Caladrius Biosciences, Cardio3 Sciences, Cellonis Biotechnology, Cytori Therapeutics, FCB-Pharmicell Co. Ltd., Gamida Cell, Geron Corporation, LifeCell, Ixion Biotechnology, Medipost Co. Ltd., Mesoblast, Neuralstem, Inc., NeuroGeneration, Inc., NuVasive, Inc., Orthofix, Osiris Therapeutics, Pfizer, ReNeuron, Skye Orthbiologics, LLC, Stem Cell Therapeutics, STEMCELL Technologies, StemCells, Inc., Stemedica Cell Technologies, Inc., Stempeutics Research, TiGenix, and ViaCyte."
& here
https://globenewswire.com/news-release/2017/09/20/1125383/0/en/Stem-Cells-Market-to-reach-US-270-5-bn-by-2025-globally-Transparency-Market-Research.html
Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc
& this report
https://www.prnewswire.com/news-releases/global-stem-cell-therapy-for-osteoarthritis-pipeline-analysis-report-2017-300549315.html
"The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.
Major companies
Mesoblast
Regeneus
U.S. Stem Cell
Anterogen
Asterias Biotherapeutics"
& a lot more is out there.
$USRM is on track for a $8-$10 million rev 2018 year even if growth slows.
BELOW ARE USRM's Key growing FINANCIALS in simple form
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017
Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)
Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017
2016 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11674975
2017 Q1 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12033381
2017 Q2 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12218852
2017 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12365541
#USRM #STEMCELLS #FDA $USRM
Thanks for the discount everyone. The imaptiance is hillarious. Wait for it...... :)
The buying end of day was nice yesterday, new base around .045-.05 and the bounce off .035 (last resistance) last Wednesday was beautiful.
This stock is building strength and a golden cross is in the horizon
$USRM in 1 year has ~X3 Profits,~X2 revenues,~X4 Assets,~X3.5 Cash from Sept 2016-2017, and look to be set up for a move to new highs. USRM brought in $1.5 million in revs & $1 million of gross profit last Q alone
http://www.nasdaq.com/symbol/usrm/revenue-eps
That link above paints a clear picture of where the company is headed
There is so much more going for the company now versus earlier this year when it was trading with a VWAP between $.075-$.14 for 80+ trading days and especially last year or what ever happened almost ten years ago. I am looking forward to more and more revenue growth with overseas expansion with their Kuwait clinic and hopefully more trials and updates on RMAT. One big spark and the game changes.
A $16 million market cap @ $.045 could easily be $100mil market cap which would be ~$.30/share. A valuation correction is well over due if you ask me and it seems others are beginning to agree.
They doubled revs and tripled profits in 1 year and the stem cell market is growing at an insane rate.
https://www.ihealthcareanalyst.com/global-stem-cell-therapy-market/ Mentioned here as Bioheart
"The global stem cells market was approximately 13 billion dollars in 2016, and from 2017, the expected annual growth rate is 14.7%, which would expand the market to 29.6 billion dollars by 2021."
"Major players operating in the global stem cell therapy market and profiled in this report include Aastrom Biosciences, Alliancells Bioscience Co. Ltd., AlloCure, Inc., Anterogen Co. Ltd., Astellas Pharma (Ocata Therapeutics/Advanced Cell Technology), Baxter Healthcare, Bioheart, BrainStorm Therapeutics, Caladrius Biosciences, Cardio3 Sciences, Cellonis Biotechnology, Cytori Therapeutics, FCB-Pharmicell Co. Ltd., Gamida Cell, Geron Corporation, LifeCell, Ixion Biotechnology, Medipost Co. Ltd., Mesoblast, Neuralstem, Inc., NeuroGeneration, Inc., NuVasive, Inc., Orthofix, Osiris Therapeutics, Pfizer, ReNeuron, Skye Orthbiologics, LLC, Stem Cell Therapeutics, STEMCELL Technologies, StemCells, Inc., Stemedica Cell Technologies, Inc., Stempeutics Research, TiGenix, and ViaCyte."
& here
https://globenewswire.com/news-release/2017/09/20/1125383/0/en/Stem-Cells-Market-to-reach-US-270-5-bn-by-2025-globally-Transparency-Market-Research.html
Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc
& this report
https://www.prnewswire.com/news-releases/global-stem-cell-therapy-for-osteoarthritis-pipeline-analysis-report-2017-300549315.html
"The expected growth is because of increasing awareness of osteoarthritis and increasing diagnosis rates, rising older population, and increasing cases of obesity. Osteoarthritis is directly related to obesity, with approximately 37% of osteoarthritis patients suffering from obesity.
Major companies
Mesoblast
Regeneus
U.S. Stem Cell
Anterogen
Asterias Biotherapeutics"
& a lot more is out there.
$USRM is on track for a $8-$10 million rev 2018 year even if growth slows.
BELOW ARE USRM's Key growing FINANCIALS in simple form
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017
Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)
Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017
2016 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11674975
2017 Q1 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12033381
2017 Q2 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12218852
2017 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12365541
#USRM #STEMCELLS #FDA $USRM
Video games on the way
USRM has ~X2 revs, ~X3 profits, ~X4 Assets, ~X3.5 Cash in 1 year (from Sept 2016-2017) set up for move to new highs, and brought in $1.5 million in revs & $1 million of gross profit last Q alone
There is so much more going for the company now versus earlier this year when it was trading with a VWAP between $.075-$.14 for 80+ trading days and especially last year or what ever happened almost ten years ago. I am looking forward to more and more revenue growth with overseas expansion with Kuwait and hopefully more trials and updates on RMAT. One big spark and the game changes.
A $15.5 million market cap @ $.0469 could easily be $100mil market cap which would be ~$.30/share. I have seen much much much worse see much higher. A valuation correction is well over due if you ask me and it seems others are beginning to agree. The company knows what it needs to do, they have said time and time again . They doubled revs and tripled profits in 1 year and the stem cell market is growing at an insane rate. Thanks for the cheap shares, especially the last 3 months.
Key growing financials
ASSETS
$283k Jun 2016
$413k Sep 2016
$427k Dec 2016
$1385k Mar 2017
$1632k Jun 2017
$1700k Sept 2017
Revenues
$678k Jun 2016
$729k Sep 2016
$964k Dec 2016
$1154k Mar 2017
$1386k Jun 2017 (Gross profit now $985k vs 443k last Jun 2016)
$1507k Sept 2017 (Gross profit now $1024k vs $397k last Sept 2016)
Cash and Cash Equivalents
$130k Jun 2016
$246k Sep 2016
$270k Dec 2016
$619k Mar 2017
$930k Jun 2017
$957k Sept 2017
2016 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11674975
2017 Q1 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12033381
2017 Q2 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12218852
2017 Q3 https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12365541
#USRM #STEMCELLS #FDA $USRM